Cardiodynamics International (MM) (CDIC) Quote

This is a completely different company listed on the real Nasdaq not the OTC, they is no JB, petel or any of those scams. This is a real compnay with real assets and real revenue.

I guess my first question is whether or not any of the players here have ANY connection to Medify or Petel or Cannonball800 or Columbia River.....I don't like seeing JB's fingerprints anymore.

what do you mean what is the deal. the stock is a true winner.

OK - you got my attention, but it is very short. What's the deal here?

Excellent potential

Global Research Services Announces Strategic Alliance Agreement with CardioDynamics

ROCKVILLE, Md., Mar 17, 2008 (BUSINESS WIRE) -- Global Research Services, LLC (GRS) announced today that it has entered into a strategic alliance with CardioDynamics (Nasdaq:CDIC). The agreement authorizes GRS to utilize CardioDynamics' impedance cardiography (ICG) technology for advanced processing of noninvasive hemodynamic ICG data. CardioDynamics ICG products enable GRS to provide expanded biometrics and data management services in support of clinical trials. Combining the strengths of both companies will allow biotechnology, pharmaceutical, and device companies and clinical research sites to obtain the benefits of enhanced cardiac safety monitoring in Phase I through IV clinical trials.

GRS has recently completed several programs using this state of the art technology to rapidly upload data from CardioDynamics' proprietary BioZ(R) ICG technology and BioZport(R) application software. Investigators and sponsors can easily view reports and detailed cardiovascular tables and graphs created from real-time trial data through secure online portals, assisting in faster decisions related to dose selection, safety outcomes, and therapeutic efficacy of cardio-active agents.

CardioDynamics' proprietary BioZport(R) application software was designed to meet FDA's 21 CFR Part 11 and HIPAA requirements and provides real-time transmission of ICG data for rapid assessment of both desired and adverse effects of candidate compounds. With the increasing focus of regulatory agencies on cardiac safety assessment of new compounds, CardioDynamics and GRS are pleased to provide this enhanced capability to the clinical trial market.

Dr. Sandra Garrett, Executive Chair, GRS said, "This technology, coupled with our Oracle Clinical data management capabilities clearly elevates the capability of cardiac safety monitoring and evaluation in research settings."

Michael K. Perry, CEO, CardioDynamics, added "We are very pleased to partner with GRS and believe that their data management capabilities, their highly regarded reputation in clinical research, as well as extensive global experience make them an excellent strategic alliance partner. With the recent challenges of FDA-approved drugs having serious cardiac side effects, including death, we believe this is an ideal application for our proprietary technology."

Global Research Services (GRS) is a multi-national contract research organization supplying a full range of clinical trial services to the pharmaceutical, biotech, and medical device communities. Headquartered in Maryland, GRS operates offices in North America, Europe and China and reaches clients worldwide through its Internet-based Oracle Clinical platform. www.grs-cro.com.

SOURCE: Global Research Services, LLC

CONTACT: Global Research Services
Marisa Pawlewicz
301-296-4742
mpawlewicz@grs-cro.com
or
CardioDynamics
Rhonda Rhyne
858-535-0202 x1013
rrhyne@cdic.com
www.cdic.com

Copyright Business Wire 2008

CEO publicly states the company should be valued 8-10 current market value.

Value has raised on the past couple of days and the stock finished up 20% after market on Friday and is up an additional 2% today for a total 22% jump from Friday's market close.